Plain-English translation of NCT07242014 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Prostate Cancer research guide โThis study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This trial is testing a new imaging agent called 68Ga-XACP3 that may help doctors detect prostate cancer more effectively. The medication is designed to highlight cancer cells during a special imaging scan called PET/CT. Researchers will compare how well this new imaging approach works compared to the standard prostate cancer imaging method currently used in clinical practice.
Currently, doctors use a standard imaging method to find prostate cancer and detect whether it has returned after treatment. Researchers believe this new medication may be even better at finding cancer cells, which could help doctors catch the disease earlier or monitor patients more accurately.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive a single injection of the new imaging medication into your vein and then undergo a PET/CT imaging scan. You will also have the standard prostate cancer imaging scan performed. The study team will compare the results of both scans to see how well the new medication detects cancer. Your participation involves a single visit or coordinated visits for both imaging procedures.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
China
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment target
~60 participants
Started
September 2025
Primary completion
October 2027
Age range
18 Years โ 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Liang Zhao
The First Affiliated Hospital of Xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.